ArticleBJS open2026
Prediagnostic serum iodine and selenium in relation to breast cancer survival.
Article in BJS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTrace elements like iodine have been suggested to be associated with breast cancer due to their antioxidant properties and ecological differences in incidence and mortality. Yet, there are no epidemiological studies on breast cancer prognosis in relation to iodine levels. The primary aim of this study was to investigate the association between prediagnostic serum iodine levels and breast cancer survival. A secondary aim was to examine if the potential association was modified by serum selenium levels.
methodsThis study included women diagnosed with primary invasive breast cancer (1991-2013) from the Malmö Diet and Cancer Study (1991-1996). The patients were divided into quartiles depending on their serum iodine levels at baseline. Crude and multivariable-adjusted Cox regression analyses were used to obtain hazard ratios with 95% confidence intervals, for breast cancer-specific and overall mortality, with follow up until 31 December 2018. Analyses were additionally stratified by selenium levels (below versus above the median).
resultsOut of 17 035 female participants of the Malmö Diet and Cancer Study, 918 patients with breast cancer were included in this study. The mean(standard deviation) follow-up time was 11.4(6.0) years. The adjusted hazard ratios for breast cancer-specific and overall mortality for the highest iodine quartile compared with the lowest were 1.26 (95% confidence interval 0.79 to 1.99) and 1.27 (0.92 to 1.75). Among women with high selenium, high iodine levels were associated with a high breast cancer-specific and overall mortality; hazard ratios of 1.90 (1.09 to 3.32) and 1.81 (1.26 to 2.61), respectively. High selenium levels were associated with a lower breast cancer-specific and overall mortality; the adjusted HRs were 0.69 (0.50 to 0.95) and 0.73 (0.58 to 0.91).
conclusionHigh serum iodine was weakly associated with mortality overall and significantly associated among women with high selenium, whereas serum selenium alone was inversely associated with mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.